Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Children's Hospital of Orange County
Modality
Small molecule
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05501899CT.gov Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Drug-Induced Liver Injury
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Levocarnitine (this asset) | Children's Hospital of Orange County | Early P1 | C · 39 |
| Ursodeoxycholic Acid | Taipei Veterans General Hospital, Taiwan | P4 | BB |
| Abemaciclib | University of Milano Bicocca | Unk | D |
| Palbociclib | University of Milano Bicocca | Unk | D |
| Ribociclib | University of Milano Bicocca | Unk | D |
| Silymarin | Tanta University | P2/3 | NR |
| mt2004 | Xi'An Aolitai Pharmaceutical Technology Co Ltd | P2 | NR |
Other indications for Levocarnitine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Spinal Muscular Atrophy | — | P3 | BB · 64 |
| Cognitive Disorder | — | P4 | B · 59 |
| Tinnitus | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Levocarnitine in Drug-Induced Liver Injury. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/levocarnitine-drug-induced-liver-injury
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →